Amyopathic dermatomyositis may be on the spectrum of autoinflammatory disease: A clinical review.
Saika SharmeenLisa Christopher-StineJoann N SalveminiPeter GorevicRichard ClarkQingping YaoPublished in: Rheumatology and immunology research (2024)
Systemic autoinflammatory diseases (SAIDs) are distinct from autoimmune diseases. The former primarily results from abnormal innate immune response and genetic testing is crucial for disease diagnosis. Similar cutaneous involvement is a main feature for both SAID and dermatomyositis (DM), so they can be confused with each other. A literature search of PubMed and MEDLINE was conducted for relevant articles. The similarities and differences between these two types of diseases were analyzed. We found phenotypic similarities between these two types of disorders. Accumulating data supports a major role of the innate immune system and a similar cytokine profile. Molecular testing using an autoinflammatory disease gene panel may help identify SAID patients from the DM population and may offer therapeutic benefit using interleukin-1 (IL-1) inhibitors. A subset of DM, notably amyopathic dermatomyositis in the absence of autoantibodies may be on the spectrum of autoinflammatory disease.
Keyphrases
- immune response
- interstitial lung disease
- systemic sclerosis
- end stage renal disease
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- newly diagnosed
- systematic review
- chronic kidney disease
- ejection fraction
- gene expression
- electronic health record
- genome wide
- adipose tissue
- dendritic cells
- skeletal muscle
- deep learning
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- inflammatory response
- glycemic control
- genome wide identification